Pharmaceutical Technology's Ninth Annual Employment Survey - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Pharmaceutical Technology's Ninth Annual Employment Survey


Pharmaceutical Technology



Table III: Percentage of respondents receiving the following employer-provided benefits.
Benefits. The most common benefits include health insurance; dental, vision, or supplemental health insurance; life insurance; and employer-provided 401k match contributions (see Table III). Other benefits that were reported but not listed in the questionnaire include stock awards, car and gas allowance, and health-club memberships.

On average, employees are granted 10 paid public holidays and 17 paid vacation days, though most took only 14 of these days for vacation and admitted to doing some work (e.g., checking e-mail, returning calls) for at least 5 of these days (one more day than last year).

Attitudes toward current employment

Survey participants indicated how strongly they agreed or disagreed with the following statements:
  • I believe my work is fully valued by my employer.
  • I believe my present job is secure.
  • In my present job, I use my skills and training to the fullest extent.
  • Given the opportunity, I would leave my present job.


Table IV: Opinions toward current employment.
Most respondents continue to feel secure in their jobs, agree that their employer values their work, and believe that they use their skills to the fullest extent in their present jobs (see Table IV). Nonetheless, 53% of workers either agreed or strongly agreed that they would leave their present job if given the opportunity. These responses all agree very closely with last year's.

As in previous years, income, geographic location, and the opportunity for professional advancement were the three most important factors that would be taken into consideration for making this change (with 71%, 48%, and 41%, respectively). Geographic location was also one of the least important factors for making a job change behind scientific opportunities and vacation entitlement.


Figure 6
Survey participants were asked to anonymously describe what they enjoy best and least in their jobs. Hands down, the most enjoyable parts of every job are the intellectual challenge, variety, and opportunities. As one respondent indicated, "I enjoy the challenge of solving issues, thinking outside the box, and constantly being on the edge of failure or great success." Another answers, "The variety! There is never a dull moment!" Clearly, the industry remains a passionate, dedicated work environment.

Like in any industry, however, workers complain of being bogged down by politics, red tape, and poor communication with upper management. Respondents indicate they are sometimes "punished" for risk-taking and that company bureaucracy and wasteful management hinder progress and flexibility. When asked to describe the least enjoyable aspects of the job, one respondent replied, "Interference in execution of my daily job functions by superiors who do not know/understand the approach I am using. Also, setting of project goals and directions by incompetent nonscientific personnel who do not possess a real understanding of customer needs and markets in the areas of work I am involved in." Also weighing in were issues such as long work hours and coworker personality conflicts.


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
32%
Breakthrough designations
8%
Protecting the supply chain
40%
Expedited reviews of drug submissions
8%
More stakeholder involvement
12%
View Results
Jim Miller Outsourcing Outlook Jim Miller Health Systems Raise the Bar on Reimbursing New Drugs
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerThe Mainstreaming of Continuous Flow API Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler Industry Seeks Clearer Standards for Track and Trace
Siegfried Schmitt Ask the Expert Siegfried SchmittData Integrity
Sandoz Wins Biosimilar Filing Race
NIH Translational Research Partnership Yields Promising Therapy
Clusters set to benefit from improved funding climate but IP rights are even more critical
Supplier Audit Program Marks Progress
FDA, Drug Companies Struggle with Compassionate Use Requests
Source: Pharmaceutical Technology,
Click here